A first heart attack, stroke or cardiovascular death occurred in 12.0% on dulaglutide against 13.4% on placebo. It was published in The Lancet in 2019.1
How the trial was run
REWIND ran at 371 sites in 24 countries. Participants were enrolled between August 2011 and August 2013 and were seen at least every 6 months. Their average age was 66.2, their median HbA1c 7.2%, and 46.3% were women. A median HbA1c of 7.2% means many participants had fairly well-controlled blood sugar at the start, close to the common target of under 7% used in the trials of these medicines.1
Two features set REWIND apart. It was long, with a median of 5.4 years of follow-up. And most participants did not have established cardiovascular disease. The Trulicity label says 31.5% had confirmed cardiovascular disease, such as a past heart attack, a past ischemic stroke or a procedure to open an artery, while 62.8% had multiple risk factors without established disease.2 In LEADER, by contrast, 80% of participants already had vascular or kidney disease or heart failure.3
What it found
- The main outcome occurred in 594 of 4,949 people on dulaglutide, 12.0%, and 663 of 4,952 on placebo, 13.4%.
- As rates, that is 2.4 against 2.7 events per 100 person-years, a hazard ratio of 0.88.
- Death from any cause was 10.8% against 12.0%, a difference that was not statistically clear.
- On the Trulicity label's breakdown, non-fatal stroke occurred in 2.7% against 3.5%, a hazard ratio of 0.76.
Gerstein et al., 2019; TRULICITY label, section 14.5.1,2
On the basis of REWIND, Trulicity is approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. The second half of that wording reflects who was in the trial.2
Side effects
Stomach and gut events were reported during follow-up by 47.4% on dulaglutide and 34.1% on placebo.1 In the Trulicity label's placebo-controlled trials, nausea was reported by 21.1% on 1.5 mg against 5.3% on placebo.2 Our page on nausea on a GLP-1 covers what helps.
How to read the result
The hazard ratio of 0.88 is close to LEADER's 0.87 for liraglutide and smaller than SUSTAIN 6's 0.74 for semaglutide.4,5 Because REWIND enrolled many people without established heart disease, its placebo group had 2.7 events per 100 person-years, and its result speaks to a broader group than trials limited to people with vascular disease. In absolute terms, 1.4 fewer people in every 100 had a major heart event over about five years, roughly one for every 71 people treated, a figure we calculated from the published percentages. The authors' conclusion was that dulaglutide could be considered for blood sugar control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or risk factors.1
Limits
REWIND enrolled only people aged 50 or older, so it says nothing direct about younger adults. It tested only the 1.5 mg dose; the higher Trulicity doses of 3 mg and 4.5 mg were added later and were not part of it.2 It was funded by Eli Lilly and Company, the maker of dulaglutide.1 Our page on Ozempic and Mounjaro covers the weekly diabetes injections most used today.
Sources
- Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121-130. Funded by Eli Lilly and Company. doi:10.1016/S0140-6736(19)31149-3
- TRULICITY (dulaglutide) injection prescribing information. Eli Lilly and Company; DailyMed, version published August 10, 2026; sections 1, 2, 6.1 and 14.5. dailymed.nlm.nih.gov
- VICTOZA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version published November 17, 2025; section 14. dailymed.nlm.nih.gov
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med 2016;375:311-322. doi:10.1056/NEJMoa1603827
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med 2016;375:1834-1844. doi:10.1056/NEJMoa1607141
Related analyses
Ozempic vs Mounjaro: what the head-to-head trial and the two labels show
When to take your GLP-1 shot: time of day, changing the day and time zones
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Ozempic side effects: how common each one is by dose, and when they ease
Log your doses, blood sugar and blood pressure in one place.
Open Dose Insider